Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...
The First International Symposium on Pheochromocytoma ... Closely related tumors of extra-adrenal sympathetic and parasympathetic paraganglia are classified as extra-adrenal paragangliomas.
genetic condition called extra-adrenal pheochromocytoma or paraganglioma. It meant his body produced adrenaline secreting tumors that created a cardiac scare. Potts would have episodes where it ...
The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
The Rahway, N.J., drugmaker on Monday said the application covers Welireg for patients 12 years and older with advanced, unresectable or metastatic pheochromocytoma and paraganglioma. The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback